Taiga Biotechnologies, Inc. is developing a new class of cell-based therapies utilizing autologous immune cells and allogeneic stem cells.
New class of cellular therapy, with an agnostic approach.
Platform technology with “Plug-and-Play” features.
Product manufacturing time - less than 24 hours.
Access to global markets with active clinical trials.
Opportunities for additional platforms & products.